SCOTT TAYLOR: Open Payments
NPI 1477517878 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,843 in 108 payments from 18 companies in 2025. Trend: 2023 $2,432 · 2024 $2,947 · 2025 $1,843
Food & beverage: $1,843
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $415 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $219 |
| GlaxoSmithKline, LLC. | 9 | $161 |
| Amgen Inc. | 12 | $159 |
| AstraZeneca Pharmaceuticals LP | 6 | $156 |
| Novo Nordisk Inc | 10 | $149 |
| PFIZER INC. | 6 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| Exact Sciences Corporation | 3 | $85 |
| Lilly USA, LLC | 3 | $78 |
Products named: XIFAXAN, UBRELVY, TRELEGY ELLIPTA, OTEZLA, VRAYLAR, QULIPTA, CAPLYTA, The Cologuard Plus Collection Kit.
Industry payments across NY — which companies pay providers there.
